Cullinan Oncology reports Q4 2021 net loss of $34.4M; cash $430.9M through 2024

Cullinan Therapeutics, Inc.

Net loss $34.4M in Q4 2021 vs $18.4M in Q3 2021; FY 2021 net loss $67.5M vs $59.5M in FY 2020.
Cash and investments $430.9M as of Dec 31, 2021, expected to fund operations through 2024.
CLN-081 Phase 1/2a data: 39% confirmed PR at 100mg BID; median DOR >15 months, PFS 12 months.
CLN-081 received FDA Breakthrough Therapy Designation in Jan 2022; regulatory update expected Q1 2022.
CLN-049 and CLN-619 first-in-human dosing initiated Dec 2021; initial data expected by mid-2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.